Genomic insights into inherited bone marrow failure syndromes in a Korean population

Jong‐Mi Lee,Hoon Seok Kim,Jaeeun Yoo,Jaewoong Lee,Ari Ahn,Hanwool Cho,Eun Hee Han,Jin Jung,Jae Won Yoo,Seongkoo Kim,Jae Wook Lee,Bin Cho,Nack‐Gyun Chung,Myungshin Kim,Yonggoo Kim
DOI: https://doi.org/10.1111/bjh.19509
2024-05-13
British Journal of Haematology
Abstract:This study elucidated the genomic landscape of inherited bone marrow failure syndromes (IBMFS) in 130 Korean patients through targeted next‐generation sequencing (NGS) and clinical exome sequencing (CES). Whole genome sequencing (WGS) and chromosomal microarray (CMA) were selectively applied in cases with negative initial results. Genomic diagnosis was achieved for 50% of the cohort, with classic IBMFSs detected in 33 patients predominantly via targeted NGS (85%) and CES (88%), and the recently defined AMeD syndrome identified exclusively through CES in two patients. Additional findings included identification of copy number variations and mutations in previously unexplored regions in two patients using CMA and WGS. Furthermore, 30 patients were diagnosed with a variety of other congenital disorders, demonstrating the value of comprehensive genomic analysis in diagnosing and managing IBMFS and associated conditions. Summary Inherited bone marrow failure syndromes (IBMFS) pose significant diagnostic challenges due to overlapping symptoms and variable expressivity, despite evolving genomic insights. The study aimed to elucidate the genomic landscape among 130 Korean patients with IBMFS. We conducted targeted next‐generation sequencing (NGS) and clinical exome sequencing (CES) across the cohort, complemented by whole genome sequencing (WGS) and chromosomal microarray (CMA) in 12 and 47 cases, respectively, with negative initial results. Notably, 50% (n = 65) of our cohort achieved a genomic diagnosis. Among these, 35 patients exhibited mutations associated with classic IBMFSs (n = 33) and the recently defined IBMFS, aplastic anaemia, mental retardation and dwarfism syndrome (AmeDS, n = 2). Classic IBMFSs were predominantly detected via targeted NGS (85%, n = 28) and CES (88%, n = 29), whereas AMeDS was exclusively identified through CES. Both CMA and WGS aided in identifying copy number variations (n = 2) and mutations in previously unexplored regions (n = 2). Additionally, 30 patients were diagnosed with other congenital diseases, encompassing 13 distinct entities including inherited thrombocytopenia (n = 12), myeloid neoplasms with germline predisposition (n = 8), congenital immune disorders (n = 7) and miscellaneous genomic conditions (n = 3). CES was particularly effective in revealing these diverse diagnoses. Our findings underscore the significance of comprehensive genomic analysis in IBMFS, highlighting the need for ongoing exploration in this complex field.
hematology
What problem does this paper attempt to address?